• About
  • Advertise
  • Privacy & Policy
  • Contact
HK Businesswire
  • Home
  • News
    • All
    • Business
    • Politics
    • PR Newswire
    • Science
    • World

    EC election ‘open, honest and fair’, says David Lok

    Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

    Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

    APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

    APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

    Fossil fuels still missing from latest COP31 draft

    HK-Chile working-holiday scheme to start next year

    HK to contribute to global bay area cooperation: FS

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • PR Newswire
  • Business
  • World
  • Entertainment
  • Sports
  • Tech
    • All
    • Apps
    • Gadget
    • Mobile
    • Startup

    Cathay Cargo Launches AI Compliance Tool to Streamline Global Trade Operations

    PCCW Global and Druid Technology Partner on Belt and Road IoT Connectivity

    Alipay Launches Domestic Full-Stack Intelligent Agent Platform in Hangzhou

    HKT Posts 4% Profit Rise Amid Steady Local Recovery and AI-Driven Demand

    Alipay Launches AI-Powered Version ‘Abao’ to Streamline Services

    Xiaohongshu Prepares Confidential Hong Kong IPO Filing

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
  • Feature
No Result
View All Result
  • Home
  • News
    • All
    • Business
    • Politics
    • PR Newswire
    • Science
    • World

    EC election ‘open, honest and fair’, says David Lok

    Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

    Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

    APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

    APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

    Fossil fuels still missing from latest COP31 draft

    HK-Chile working-holiday scheme to start next year

    HK to contribute to global bay area cooperation: FS

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • PR Newswire
  • Business
  • World
  • Entertainment
  • Sports
  • Tech
    • All
    • Apps
    • Gadget
    • Mobile
    • Startup

    Cathay Cargo Launches AI Compliance Tool to Streamline Global Trade Operations

    PCCW Global and Druid Technology Partner on Belt and Road IoT Connectivity

    Alipay Launches Domestic Full-Stack Intelligent Agent Platform in Hangzhou

    HKT Posts 4% Profit Rise Amid Steady Local Recovery and AI-Driven Demand

    Alipay Launches AI-Powered Version ‘Abao’ to Streamline Services

    Xiaohongshu Prepares Confidential Hong Kong IPO Filing

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
  • Feature
No Result
View All Result
HK Businesswire
No Result
View All Result
Home News PR Newswire

Ascletis Submits IND Application to the U.S. FDA for ASC30_39 FDC, a Potentially First-in-Class Oral Small Molecule Fixed-Dose Combination of GLP-1R Agonist and Selective Amylin Receptor Agonist, for the Treatment of Obesity

PR Newswire by PR Newswire
11 November 2026
in PR Newswire
0
Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

–  ASC30_39 FDC, a once-daily oral fixed-dose combination (FDC) tablet of small molecule GLP-1R agonist ASC30 and small molecule selective amylin receptor agonist ASC39, is the first co-formulation of an oral GLP-1 and an oral amylin to reach Investigational New Drug submission.

–  ASC30_39 FDC demonstrated highly favorable pharmacokinetics with excellent oral bioavailability, high drug exposure and a long half-life.

–  ASC30 is a once-daily oral small molecule GLP-1R agonist currently in two global pivotal Phase III studies (AURORA-1 and AURORA-2).

–  ASC39 demonstrated eloralintide-like amylin selectivity (40-fold for hAMY1R over hCTR) and efficacy in preclinical models.

–  ASC30_39 FDC demonstrated excellent compatibility between ASC30 and ASC39, with room temperature stability and a small pill size.

HONG KONG, Nov. 11, 2026 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) announces today the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ASC30_39 FDC, a once-daily oral fixed-dose combination (FDC) tablet of small molecule GLP-1R agonist ASC30 and small molecule selective amylin receptor agonist (SARA) ASC39, for the treatment of obesity.

“ASC30_39 FDC is the first co-formulation of an oral GLP-1 and an oral amylin to reach IND submission, combining two validated, complementary mechanisms for weight management in a single once-daily tablet.” said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, “By pairing the potentially best-in-class efficacy and gastrointestinal tolerability of ASC30 with the first eloralintide-like oral small molecule amylin, we believe ASC30_39 FDC has the potential to offer patients a highly differentiated and convenient oral treatment option for obesity.”

The IND submission builds upon the recent milestones of Ascletis’ oral small molecule portfolio. ASC30 is currently in two global pivotal Phase III studies (AURORA-1 and AURORA-2), enrolling approximately 4,600 participants with obesity or overweight in the U.S., Europe and Canada. Ascletis expects to report topline data from the AURORA Phase III clinical program in the third quarter of 2028. Ascletis recently announced the submission of an IND to the U.S. FDA for ASC39, its oral small molecule selective amylin receptor agonist, for the treatment of obesity.

About ASC30_39 FDC

Both ASC30 and ASC39 were discovered in-house utilizing Ascletis’ Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) technology. ASC30_39 FDC was developed utilizing Ascletis’ proprietary formulation technology and demonstrated excellent compatibility between ASC30 and ASC39, with room temperature stability and a small pill size.

Dosed orally in dogs, ASC30_39 FDC tablets demonstrated excellent oral bioavailability, high drug exposure and a long half-life of up to 12 hours. These key pharmacokinetic parameters of ASC30_39 FDC are consistent with those observed for the respective monotherapies in a head-to-head dog study. (Press Release)

ASC30 is a once-daily oral small molecule GLP-1R agonist currently in two global pivotal Phase III studies (AURORA-1 and AURORA-2), and had a favorable gastrointestinal (GI) tolerability profile with half the rate of vomiting versus orforglipron when both drugs were dosed with weekly titration in non-head-to-head studies. (Press Release)

ASC39 is a potent oral small molecule selective amylin receptor agonist that was 40-fold more selective for human amylin 1 receptor (hAMY1R) over human calcitonin receptor (hCTR) and produced a 6.6% placebo-adjusted body weight reduction after once-daily oral administration for six consecutive days in diet-induced obese (DIO) rats, similar to eloralintide at 5.6%. (Press Release)

About Ascletis Pharma Inc.

Ascletis Pharma Inc. (1672.HK) is a fully integrated biotechnology company focused on discovering, developing and commercializing potentially first-in-class and best-in-class therapeutics for metabolic diseases, including obesity and diabetes. Leveraging its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP) and Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has built a wholly in-house pipeline of oral small molecules and peptides targeting GLP-1R, GIPR, GCGR and amylin pathways. Ascletis is advancing a robust pipeline of 15 differentiated assets leveraged from six new molecular entities (three small molecules and three peptides), which are being developed both as monotherapies and in combination. Its lead program, ASC30, a once-daily oral small molecule GLP-1R agonist, is being evaluated in two global Phase III studies in obesity. The Company’s pipeline also includes oral small molecule dual and triple agonist fixed-dose combinations, a selective amylin receptor agonist, injectable peptide agonists and combinations spanning dual to quadruple agonism designed for once-monthly to once-quarterly subcutaneous dosing, and oral peptide agonists and combinations designed for once-weekly dosing.

For more information, please visit www.ascletis.com.

Contact:

Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
Peter.vozzo@icrhealthcare.com 

Ascletis Pharma Inc. PR and IR Teams
+86-181-0650-9129 (China)
pr@ascletis.com / ir@ascletis.com 

Tags: prnewswire
PR Newswire

PR Newswire

PR Newswire is the industry’s leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world.

Read More

CARsgen Presents First Clinical Data on Its In Vivo CAR-T Product Candidate CT1182

CARsgen Presents First Clinical Data on Its In Vivo CAR-T Product Candidate CT1182

22 November 2026
DataBeyond Showcases AI Sorting Solutions for Circular Supply Chains at COP31

DataBeyond Showcases AI Sorting Solutions for Circular Supply Chains at COP31

22 November 2026
  • Trending
  • Comments
  • Latest
Newgen reports Revenue of ₹357 crores in Q1 FY’27, up 11% Q1 YoY; Profit After Tax at ₹63 crores, up 26% Q1 YoY

Newgen Software and the Asian Institute of Digital Finance Forge Strategic Partnership to Shape the Future of Enterprise AI

10 November 2026

World Winter Sports Expo 2026 Opens, Charting a New Decade for Ice and Snow and Outdoor Industries

17 October 2026

HK five-year plan offers UK long-term prospects: CE

10 November 2026
Patriot Launches AI Matrix SSD and DRAM Series Engineered for Local AI Workloads

Patriot Launches AI Matrix SSD and DRAM Series Engineered for Local AI Workloads

19 November 2026

EC election ‘open, honest and fair’, says David Lok

22 November 2026
Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

22 November 2026
APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

22 November 2026

Fossil fuels still missing from latest COP31 draft

22 November 2026

Recent News

EC election ‘open, honest and fair’, says David Lok

22 November 2026
Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

Chongqing International Talent Exchange Conference Opens, Drawing Nobel Laureates and Global Innovators

22 November 2026
APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

APEC Business Travel Card is Linking Zhongshan with Asia-Pacific

22 November 2026

Fossil fuels still missing from latest COP31 draft

22 November 2026
HK Businesswire

Stay ahead with the latest insights on Hong Kong’s economy, finance, and investments. From market trends to policy updates, we bring you in-depth analysis and expert opinions.

📩 Subscribe to our newsletter for exclusive updates.
📍 Follow us on social media for real-time news.
📧 Contact us: info@hongkong-invest.com

Follow Us

  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2025 by HKBusinesswire.com

No Result
View All Result

© 2025 by HKBusinesswire.com